Literature DB >> 27009413

Headache and temporo mandibular disorders: epidemiological assessment.

Anna D'Urso1, Emanuela Serritella, Doria Tolevski Meshkova, Giovanni Falisi, Carlo Di Paolo.   

Abstract

BACKGROUND: Temporo mandibular disorders (TMDs) and headache are closely related pathologies. The aim of this study was to determine the prevalence, incidence, and the intensity of headache in 3304 dysfunctional patients (G1) at the Service of Clinical Gnathology of the Head-Neck Assistance Department of Umberto I Polyclinic at Sapienza University of Rome.
METHODS: G1 is composed by two subgroups of patient S1 (N.=2375) and S2 (N.=929) analyzed in different periods, respectively 1996-2006 and 2011-2013. The findings were compared with those of a control group of subjects from the general Italian population recently reported elsewhere. The prevalence of headache in the dysfunctional population was analyzed by calculating the proportion of that population who tested positive to cephalic pain for the entire study period. The incidence of headache has been calculated by determining the proportion cases of headache in TMD population, during the period analyzed among those considered at risk at the beginning of the examination period. The intensity of cephalic pain was evaluated using the Verbal Numeric Scale. Confidence Intervals (CI) at the 95% confidence level were calculated to get a precise estimate of research data.
RESULTS: Comparison of G1 and control sample did not reveal many important differences, respectively with a headache prevalence of 49.5% (95%CI 47.8%-51.2%) and 42.8%(95%CI 46.8-38.8%). However, comparison of S1, which constituted a sample similar in numbers to the control sample and was observed during a similar time period, revealed a clearly greater prevalence of headache in the dysfunctional population 67.3% (95%CI 64.3-70.3%) than in the general representative population of Italian people 42.8% (95%CI 46.8-38.8%). The incidence of headache in the dysfunctional population was 39.49% (95%CI 37.79-41.19%). Headache incidence in the first subgroup (S1) was 32.7%(95%CI 34.6-30.8%), while in S2 was 59.24%(95%CI 56.24-62.24%), demonstrating an increase of incidence in the second subgroup analyzed. In G1 the average intensity of headache was severe (VNS>50). Headache is more intense in dysfunctional patients of the second subgroups (S2) than the first subgroup (S1) VNS 24.91 (95%CI 23.11-26.71) vs. 70.00 (95%CI 67.0-73.0).
CONCLUSIONS: These findings confirm the existence of a relationship between headache and TMDs, showing that a dysfunctional patient has a greater predisposition to headache than a non-dysfunctional subject.

Entities:  

Mesh:

Year:  2016        PMID: 27009413

Source DB:  PubMed          Journal:  Minerva Stomatol        ISSN: 0026-4970


  4 in total

1.  Evaluation of Temporomandibular Disorders before and after Orthognathic Surgery: Therapeutic Considerations on a Sample of 76 Patients.

Authors:  Carlo di Paolo; Giorgio Pompa; Paolo Arangio; Anna di Nunno; Stefano Di Carlo; Daniele Rosella; Piero Papi; Piero Cascone
Journal:  J Int Soc Prev Community Dent       Date:  2017-03-29

2.  Temporomandibular Disorders and Headache: A Retrospective Analysis of 1198 Patients.

Authors:  Carlo Di Paolo; Anna D'Urso; Piero Papi; Francesco Di Sabato; Daniele Rosella; Giorgio Pompa; Antonella Polimeni
Journal:  Pain Res Manag       Date:  2017-03-21       Impact factor: 3.037

3.  Comparison of the Effectiveness of Three Different Acupuncture Methods for TMD-Related Pain: A Randomized Clinical Study.

Authors:  Emanuela Serritella; Gabriella Galluccio; Alessandra Impellizzeri; Paola Di Giacomo; Carlo Di Paolo
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-30       Impact factor: 2.629

Review 4.  Genetic overlap between temporomandibular disorders and primary headaches: A systematic review.

Authors:  Diogo Cruz; Francisca Monteiro; Maria Paço; Manuel Vaz-Silva; Carolina Lemos; Miguel Alves-Ferreira; Teresa Pinho
Journal:  Jpn Dent Sci Rev       Date:  2022-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.